AA
SAGE

AlphaCentric Advisors’s Sage Therapeutics SAGE Stock Holding History

AlphaCentric Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$468K Buy
11,000
+5,000
+83% +$209K 0.14% 65
2021
Q3 		$266K Buy
+6,000
New +$275K 0.07% 99

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AlphaCentric Advisors's SAGE Position: Q4 2021 in Review

AlphaCentric Advisors increased its Sage Therapeutics (SAGE) stake by 83% in Q4 2021, buying an estimated $209K and bringing the position to 11,000 shares worth $468K. The position accounts for 0.14% of the portfolio, ranked #65.

AlphaCentric Advisors first reported a position in SAGE in Q3 2021 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

  • AlphaCentric Advisors held 11,000 shares of Sage Therapeutics worth $468K as of Q4 2021.
  • AlphaCentric Advisors bought 5,000 Sage Therapeutics shares in Q4 2021, an estimated $209K.
  • Sage Therapeutics made up 0.14% of AlphaCentric Advisors's portfolio in Q4 2021, its #65 holding.
  • AlphaCentric Advisors first reported a position in Sage Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.